Tenaya Therapeutics Inc (NASDAQ: TNYA) is a clinical-stage biotechnology company developing gene therapy treatments for heart disease. The company has no approved products and generates no product revenue as of its 10-K filed March 11, 2026. Tenaya's pipeline includes TN-201, a recombinant adeno-associated virus (rAAV) vector delivering the MYBPC3 gene for cardiomyopathy, and TN-301, another gene therapy candidate, both protected by issued U.S. patents and pending applications worldwide. The company carries an accumulated deficit on its balance sheet and funds operations through capital markets activity rather than product sales. Faraz Ali serves as Chief Executive Officer. Tenaya competes for talent and capital against other biotechnology companies with greater financial resources and longer operating histories, per the FY2025 10-K filing.

Revenue model

Tenaya has no approved products and no product revenue as of the 10-K filed March 11, 2026. Operations are funded through equity financing, reflected in an accumulated deficit on the December 31, 2025 balance sheet.

Products and services

TN-201: rAAV gene therapy encoding MYBPC3 for cardiomyopathy treatment, covered by four issued U.S. patents expiring 2041 (assuming fee payments) and 24 pending foreign patent applications as of the filing date. TN-301: gene therapy candidate covered by three issued U.S. patents and pending applications in multiple jurisdictions.

Customers and end markets

No commercial customers as of the 10-K filed March 11, 2026. Target end market is cardiac disease patients, specifically those with cardiomyopathy. Future commercialization subject to regulatory approval.

Value-chain role

Drug discovery and clinical-stage development. Tenaya conducts research, manages clinical programs, and holds IP on gene therapy constructs. No manufacturing, commercialization, or distribution activities disclosed in the filing excerpts.

Geographic exposure

Headquartered in the United States. Patent filings span multiple jurisdictions including Australia, Brazil, Canada, China, European Patent Office, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Saudi Arabia, Singapore, South Africa, and United Arab Emirates, per the FY2025 10-K.

Source: SEC 10-K, filed 2026-03-11

Industry: Biological Products, (No Diagnostic Substances) Peers: AVITA Medical Inc Celcuity Inc DermTech, Inc. Icosavax, Inc. IPI Legacy Liquidation Co PepGen Inc Ovid Therapeutics Inc Oric Pharmaceuticals Inc Precision BioSciences Inc